A key to improving the quality of health care is having studies that show what is and isn’t working in the real world when it comes to improving patient health while managing costs.
As these kinds of real-world studies become more commonplace with new technology, analytical tools and collaborative efforts taking hold, it is important to understand if and how they are informing health care decisions made by insurers, providers, patients and other stakeholders.
The National Pharmaceutical Council has released the findings from its second Annual Survey of Health Care Stakeholders on Attitudes and Expectations for Comparative Effectiveness Research (CER).
The survey findings show that the vast majority (95 percent) of stakeholders believe that CER is “somewhat” or “very important” to them and that the majority (77 percent) expect these studies will help improve decision-making in the next three years.
Together with HealthCore, the health outcomes research subsidiary of WellPoint, Inc., AstraZeneca is building a real-world evidence (RWE) capability. Through RWE, we conduct observational studies, taking information outside of controlled trials to create insights that stakeholders need to make better informed decisions.
Insights about unmet needs, the burden and cost of illness, treatment pathways, safety and the real-life cost effectiveness of specific therapeutic options will become more readily accessible in the years ahead. We look forward to continuing to work with stakeholders on building and applying this important research to improve patient health.